Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Citius Pharmaceuticals Inc (NASDAQ: CTXR) closed the day trading at $2.15 down -12.96% from the previous closing price of $2.47. In other words, the price has decreased by -$12.96 from its previous closing price. On the day, 1.56 million shares were traded.
Ratios:
For a better understanding of CTXR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.09 and its Current Ratio is at 0.41. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On November 30, 2021, Maxim Group started tracking the stock assigning a Buy rating and target price of $4.
Stock Price History:
Over the past 52 weeks, CTXR has reached a high of $26.75, while it has fallen to a 52-week low of $2.42. The 50-Day Moving Average of the stock is -30.77%, while the 200-Day Moving Average is calculated to be -81.00%.
Shares Statistics:
A total of 8.59M shares are outstanding, with a floating share count of 8.10M. Insiders hold about 5.74% of the company’s shares, while institutions hold 8.46% stake in the company.
Earnings Estimates
The dynamic stock of Citius Pharmaceuticals Inc (CTXR) is currently being evaluated by a team of 1.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.52, with high estimates of -$0.52 and low estimates of -$0.52.
Analysts are recommending an EPS of between $1.35 and $1.35 for the fiscal current year, implying an average EPS of $1.35. EPS for the following year is $2.98, with 2.0 analysts recommending between $4.72 and $1.25.
Revenue Estimates
Based on 3 analysts’ estimates, the company’s revenue will be $67.79M in the next fiscal year. The high estimate is $78.29M and the low estimate is $57.3M.
